GlaxoSmithKline Consumer Healthcare Limited reported standalone unaudited earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported net sales /income from operations of INR 9,398.6 million compared to INR 8,130.2 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 1,956.0 million compared to INR 1,731.4 million a year ago. Profit from ordinary activities before tax was INR 2,279.0 million compared to INR 1,964.2 million a year ago. Net Profit for the period was INR 1,564.1 million or INR 37.19 per share before and after extraordinary items compared to INR 1,319.7 million or INR 31.38 per share before and after extraordinary items a year ago. profit after tax was INR 1,560 million.

GlaxoSmithKline Consumer Healthcare Limited announced that the board of directors of the company at its meeting held on May 01, 2013, has noted the withdrawal of nomination by Horlicks Limited of Mr. Simon Scarff as the director of the company and as the Chairman of the board withe effect from close of business hours as on April 30, 2013 & accepted the resignation of Mr. Subodh Bhargava as an elected director. The board appointed Ms. Ireena Vittal as a director of the company, in the casual vacancy caused by the resignation of Mr. Subodh Bhargava.

GlaxoSmithKline Consumer Healthcare Limited, Board Meeting, May 01, 2013. Agenda: To consider and take on record the unaudited financial results for the quarter ended on March 31, 2013 with limited review done by the statutory auditors.